歐洲慢性靜脈疾病診療指南 | ESVS前言篇四

    本指南由時任ESVS大會副主席Marianne De Maeseneer女士，全權(quán)授權(quán)予紀(jì)永威教授(中國臺灣)將歐洲慢性靜脈疾病診療指南，為海峽兩岸及港澳地區(qū)以及其他使用中文服務(wù)于患者的醫(yī)生同業(yè)提供無償服務(wù)。紀(jì)教授邀請陳忠教授、符偉國教授、郭偉教授三位教授共同編譯，連續(xù)連載，為廣大醫(yī)療專業(yè)人士提供重要的資源，幫助他們根據(jù)最新的臨床證據(jù)為CVD患者制定個性化的治療方案。   

☆4.證據(jù)和建議標(biāo)準(zhǔn)☆

    歐洲心臟病學(xué)會（European Society of Cardiology，ESC）體系用于對證據(jù)和建議進(jìn)行分級。A、B或C反映了當(dāng)前證據(jù)的級別(表1)，每個建議的強(qiáng)度分為Ⅰ、Ⅱa、Ⅱb或Ⅲ級(表2)。

    為了制定建議，我們考慮了現(xiàn)有證據(jù)的優(yōu)勢和局限、益處和危害以及對臨床實踐的適用性。在正文中討論了研究方法局限性的細(xì)節(jié)、主要和次要結(jié)果的適當(dāng)性以及研究結(jié)果的一致性。

☆5.證據(jù)表☆

    委員會成員在證據(jù)表（Tables of Evidence,ToEs）中提供了選定文章的摘要，用于支持不同建議的證據(jù)。這些表格可以作為補(bǔ)充材料在網(wǎng)上獲得。

☆  4. Evidence and Recommendations criteria. ☆ 

        The European Society of Cardiology (ESC) system was used for grading evidence and recommendations. A, B, or C reflects the level of current evidence (Table1) and the strength of each recommendation was then determined to be class I, IIa, IIb, or III (Table 2).

       To formulate recommendations, the strengths and limita tions of the available evidence were considered, as well as benefit versus harm and applicability to clinical practice context. Details of study methodology limitations, appropri ateness of primary and secondary outcomes, and consistency of results across studies were discussed in the main text.

☆ 5. Tables of Evidence. ☆

       The members of the GWC provided summaries of the selected articles, used to support the evidence for the different recommendations, in Tables of Evidence (ToEs). These ToEs are available online, as Supplementary Material.